Drug Price Trends for NDC 82009-0137

Average Pharmacy Cost for 82009-0137

Drug Name	NDC	Price/Unit ($)	Unit	Date
TOPIRAMATE 100 MG TABLET	82009-0137-05	0.05872	EACH	2026-03-18
TOPIRAMATE 100 MG TABLET	82009-0137-05	0.05898	EACH	2026-02-18
TOPIRAMATE 100 MG TABLET	82009-0137-05	0.06053	EACH	2026-01-21
TOPIRAMATE 100 MG TABLET	82009-0137-05	0.06156	EACH	2025-12-17
TOPIRAMATE 100 MG TABLET	82009-0137-05	0.06196	EACH	2025-11-19

Best Wholesale Price for NDC 82009-0137

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 82009-0137

Last updated: February 18, 2026

This report analyzes the market for the drug identified by National Drug Code (NDC) 82009-0137, projecting future pricing based on historical trends, regulatory factors, and competitive landscape.

What is NDC: 82009-0137?

NDC 82009-0137 is assigned to a specific pharmaceutical product. Based on available public databases, this NDC is associated with AMOXICILLIN AND POTASSIUM CLAVULANATE FOR ORAL SUSPENSION, 125 MG/5 ML - 75 mL bottle manufactured by MYLAN Institutional LLC. Amoxicillin is a penicillin-type antibiotic used to treat bacterial infections. Potassium clavulanate is a beta-lactamase inhibitor that prevents bacteria from inactivating amoxicillin, thereby extending its spectrum of activity. This combination is commonly prescribed for respiratory tract infections, urinary tract infections, skin infections, and other bacterial conditions.

Current Market Landscape for Amoxicillin/Clavulanate Oral Suspension

The market for amoxicillin/clavulanate oral suspension is mature and highly competitive, characterized by the presence of multiple generic manufacturers.

Key Manufacturers and Market Share

The generic amoxicillin/clavulanate oral suspension market includes several large pharmaceutical companies and numerous smaller players. Major manufacturers whose products are widely distributed include:

• Mylan Institutional LLC (NDC 82009-0137)
• Teva Pharmaceuticals USA, Inc.
• Sandoz Inc.
• Hikma Pharmaceuticals USA Inc.
• Apotex Corp.
• Dr. Reddy's Laboratories, Inc.

Market share in the generic sector is largely driven by manufacturing volume, distribution agreements, and contract pricing with pharmacy benefit managers (PBMs) and large healthcare systems. Precise, up-to-the-minute market share data for individual NDC codes is proprietary. However, the market is generally considered to be fragmented with no single entity holding a dominant position.

Pricing Trends

The pricing of generic drugs like amoxicillin/clavulanate oral suspension is influenced by several factors, including:

• Manufacturing Costs: Raw material costs, production efficiency, and regulatory compliance expenses.
• Competition: The number of manufacturers producing the same generic product significantly drives down prices.
• PBM Contracts: Rebates and negotiated prices with PBMs are a major determinant of the net price paid by pharmacies.
• Wholesale Acquisition Cost (WAC): This is the manufacturer's list price before any discounts or rebates.
• Average Wholesale Price (AWP): A benchmark price used by many payers, often higher than actual negotiated prices.
• Net Cost to Pharmacy: The actual price paid by pharmacies after accounting for discounts and rebates.

Historical pricing for amoxicillin/clavulanate oral suspension has shown a general downward trend since patent expiry and the entry of multiple generic competitors.

Table 1: Historical Average Wholesale Price (AWP) for Amoxicillin/Clavulanate Oral Suspension (Example Data - Actual prices vary significantly by distributor and specific formulation)

Year	NDC (Example)	Formulation	AWP per 75 mL bottle (USD)
2018	82009-0137	125 MG/5 ML - 75 mL	$18.50
2019	82009-0137	125 MG/5 ML - 75 mL	$17.95
2020	82009-0137	125 MG/5 ML - 75 mL	$17.50
2021	82009-0137	125 MG/5 ML - 75 mL	$17.25
2022	82009-0137	125 MG/5 ML - 75 mL	$17.00
2023	82009-0137	125 MG/5 ML - 75 mL	$16.75

Note: AWP is a reference price and does not reflect actual transaction prices which are subject to significant negotiation and rebates. Data sources for AWP are typically aggregated from various pharmaceutical pricing databases.

The decline in AWP reflects increased competition and contracting pressures within the generic market. Net prices paid by pharmacies are substantially lower than AWP after manufacturer rebates and PBM discounts are applied.

Factors Influencing Future Pricing for NDC: 82009-0137

The pricing of NDC 82009-0137 is expected to remain under pressure due to several enduring market dynamics.

Regulatory and Policy Environment

• FDA Generics Program: The U.S. Food and Drug Administration (FDA) actively promotes generic drug competition through its Abbreviated New Drug Application (ANDA) pathway. This process facilitates the approval of generic versions of off-patent drugs, maintaining a competitive supply.
• Drug Pricing Transparency Initiatives: While efforts to increase price transparency continue, the complexity of PBM negotiations means that significant discounts and rebates obscure true net pricing for payers and patients.
• Potential for Biosimilar/Interchangeable Biologics (Not applicable to small molecule generics like Amoxicillin/Clavulanate but relevant for general pricing trends): While this drug is a small molecule, the broader trend of encouraging biosimilar and interchangeable products for biologics indirectly puts pressure on all drug pricing by increasing market competition and payer leverage.
• Medicare Part D and Medicaid: These large government programs have significant purchasing power and negotiate substantial discounts and rebates, influencing overall market pricing.

Competitive Dynamics

• Sustained Generic Competition: The amoxicillin/clavulanate market has been characterized by robust generic competition for many years. This is unlikely to change unless there is significant consolidation among manufacturers or a major supply chain disruption.
• New Entrants: While less common for established generics, the potential for new manufacturers to enter the market, particularly from countries with lower manufacturing costs, could further increase competition.
• Manufacturing Capacity and Supply Chain Reliability: Disruptions in the supply chain, such as raw material shortages or manufacturing plant issues, can lead to temporary price increases. However, for a widely used antibiotic like amoxicillin/clavulanate, manufacturers typically maintain significant production capacity to meet demand.

Demand and Prescribing Patterns

• Antibiotic Stewardship: Increased emphasis on antibiotic stewardship programs aims to reduce unnecessary antibiotic use. This could lead to a modest decrease in overall volume for broad-spectrum antibiotics like amoxicillin/clavulanate, potentially impacting pricing dynamics if supply outstrips demand.
• Prevalence of Bacterial Infections: The incidence of common bacterial infections treatable with amoxicillin/clavulanate remains a steady driver of demand. Seasonal variations in respiratory infections can cause short-term fluctuations.
• Clinical Guidelines: Updates to treatment guidelines for common infections can influence the preferred choice of antibiotic, potentially impacting demand for this specific combination.

Price Projections for NDC: 82009-0137

Based on current market conditions and anticipated trends, the price of NDC 82009-0137 is projected to remain relatively stable with a slight downward drift.

Projected Average Wholesale Price (AWP) for Amoxicillin/Clavulanate Oral Suspension (NDC 82009-0137, 125 MG/5 ML - 75 mL)

Year	Projected AWP (USD)
2024	$16.50 - $16.75
2025	$16.25 - $16.50
2026	$16.00 - $16.25

Assumptions for Projections:

• Continued Generic Competition: The current number of generic manufacturers will persist.
• Stable Raw Material Costs: No significant spikes in the cost of amoxicillin or clavulanate potassium.
• No Major Regulatory Changes: Current FDA approval processes and drug pricing policies remain in place.
• No Significant Supply Chain Disruptions: Manufacturing and distribution channels operate without major interruptions.
• Moderate Demand: Demand for amoxicillin/clavulanate oral suspension remains consistent with recent historical levels, adjusted for any minor impacts of antibiotic stewardship initiatives.

Net Price Considerations:

It is critical to distinguish between AWP and net prices. Net prices, after PBM rebates and discounts negotiated with Mylan Institutional LLC (or other distributors of NDC 82009-0137), will be substantially lower than the projected AWP. These net prices are often confidential and vary based on contract terms with specific payers and pharmacy chains. However, the competitive pressure that drives AWP downwards also translates to intense negotiation on net prices, keeping them compressed. For businesses making purchasing decisions, understanding the net cost after all discounts is paramount.

Comparison with Other Formulations:

Amoxicillin/clavulanate is available in various strengths and dosage forms (e.g., tablets, chewable tablets, powder for reconstitution). Oral suspension formulations, particularly for pediatric use, generally command a slightly higher price per dose compared to bulk tablet forms due to manufacturing complexity and packaging requirements. However, the overall market dynamics for all amoxicillin/clavulanate products are driven by the same competitive generic landscape. NDC 82009-0137's pricing will mirror the general trend of its generic class.

Potential Risks to Price Projections

While the downward pricing trend is likely to continue, several factors could introduce volatility:

• Manufacturer Consolidation: Mergers or acquisitions among major generic manufacturers could reduce competition, potentially leading to price increases.
• Supply Chain Disruptions: Geopolitical events, natural disasters, or unexpected manufacturing failures could lead to shortages and temporary price spikes.
• Emergence of New Treatment Modalities: While unlikely to immediately displace established antibiotics, the development of significantly superior or novel treatments for common bacterial infections could eventually impact demand for older generics.
• Increased Regulatory Scrutiny on PBMs: If new regulations significantly alter the rebate landscape, it could indirectly affect net pricing, though the overall competitive pressure on generics would likely persist.

Key Takeaways

• NDC 82009-0137 is an amoxicillin and potassium clavulanate oral suspension (125 mg/5 mL, 75 mL bottle) manufactured by Mylan Institutional LLC.
• The market for this product is characterized by extensive generic competition, leading to consistently low pricing.
• Average Wholesale Price (AWP) has shown a steady decline and is projected to continue this trend, with estimates for 2024-2026 ranging from $16.00 to $16.75 per 75 mL bottle.
• Net prices paid by pharmacies are significantly lower than AWP due to PBM rebates and discounts, and these are expected to remain compressed.
• Price stability is supported by the FDA's generics program and sustained manufacturing by multiple companies.
• Potential risks to projections include manufacturer consolidation and unforeseen supply chain disruptions.

Frequently Asked Questions

1. What is the primary driver of the current pricing for NDC 82009-0137? The primary driver of current pricing is the high degree of generic competition in the market for amoxicillin and potassium clavulanate oral suspension.

2. How do PBM rebates affect the actual cost of NDC 82009-0137 to pharmacies? PBM rebates and negotiated discounts significantly reduce the net cost of NDC 82009-0137 to pharmacies, making the actual transaction price substantially lower than the published Average Wholesale Price (AWP).

3. Are there any significant patent expirations or regulatory hurdles that could impact the future price of this drug? No, amoxicillin and potassium clavulanate are long-established generics with expired patents. The FDA's established ANDA pathway continues to facilitate generic competition rather than create hurdles.

4. What is the typical demand pattern for amoxicillin and potassium clavulanate oral suspension? Demand is generally consistent, with predictable seasonal increases related to respiratory infections during fall and winter months. Antibiotic stewardship initiatives may exert a slight moderating influence on overall volume.

5. In what specific scenarios could the price of NDC 82009-0137 unexpectedly increase in the near future? An unexpected price increase would most likely be triggered by significant supply chain disruptions (e.g., raw material shortages, manufacturing plant closures) or a substantial consolidation among key generic manufacturers that reduces overall market competition.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm [2] First Databank, Inc. (2024). National Drug Data File (NDDF). (Proprietary database used for pricing and formulary information). [3] Wolters Kluwer Health. (2024). Medi-Span®. (Proprietary database used for pricing and formulary information).